Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth Prospects and Strategic Opportunities Through 2029
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What CAGR And Valuation Are Anticipated For The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The market size of the metabolic dysfunction-associated steatohepatitis (mash) treatment has experienced significant growth in the past few years. Its projected growth will be from $2 billion in 2024 to $2.59 billion in 2025, with a compound annual growth rate (CAGR) of 29.7%. Factors contributing to this growth in the historic period include a higher number of non-alcoholic steatohepatitis cases, contemporary dietary practices, consumption of food high in processed ingredients, inactive lifestyles, and a rising occurrence of metabolic disorders.
The market size for treatment of metabolic dysfunction-associated steatohepatitis (mash) is predicted to witness substantial growth in the coming years. It is forecasted to reach the value of $7.29 billion by the year 2029, expanding at a compound annual growth rate (CAGR) of 29.5%. This projected growth for the period under discussion can be linked to the rising incidences of obesity and obesity-linked ailments, early diagnoses, mechanisms for reimbursement, insurance claims, and increasing awareness about liver disorders. Significant trends to lookout for during the forecast period encompass advancement in technology, development in the medical pipeline, strategic alliances and partnerships, bespoke medication and precision therapies, as well as investments in clinical studies and research.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp
What Core Drivers Are Expected To Influence The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market is anticipated to expand due to the escalating prevalence of obesity. Obesity, typically defined by a body mass index (BMI) of 30 or above, is a medical condition marked by excessive body fat accumulation which can adversely affect a person’s overall health. Factors such as sedentary lifestyles, unhealthy diets, and metabolic risk elements contribute to the global rise in obesity. Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatments for obese clients aim to handle insulin resistance, decrease liver fat, as well as enhance metabolic wellness through lifestyle modifications and specific therapies. The World Heart Foundation, a non-government global cardiovascular organization based in Switzerland, reported in March 2023 that around 2.3 billion adults and children globally are obese or overweight. This figure is forecasted to increase to 2.7 billion by 2025 due to the ongoing trend in obesity. Hence, the growing frequency of obesity is fueling the growth of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
What Are The Main Segment Classifications In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The metabolic dysfunction-associated steatohepatitis (mash) treatmentmarket covered in this report is segmented –
1) By Treatment: By Drug; By Therapy
2) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-User
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
Subsegments:
1) By Drug: Antifibrotic Agents; Antidiabetic Drugs; Lipid-Lowering Agents; Vitamin E; Obeticholic Acid (OCA); GLP-1 Agonists; Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy; Lifestyle Modifications (Dietary Changes, Exercise); Bariatric Surgery; Liver Transplantation
How Are Market Trends Influencing Competition In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
Leading players in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are zeroing in on the creation of innovative solutions such as liver fibrosis treatment products. These solutions are aimed at treating MASH patients who also suffer from moderate to severe liver fibrosis. The focus is to tackle the root cause of liver damage, through lifestyle changes, antivirus drugs and novel antifibrotic therapies, with the primary goal to halt or even reverse fibrosis progression, thereby improving liver function. For example, Madrigal Pharmaceuticals Inc., a US-based biopharmaceutical firm, unveiled in March 2024 that its drug Rezdiffra (resmetirom) received FDA approval, marking it as the inaugural treatment for MASH patients experiencing moderate to severe liver fibrosis. Rezdiffra, an oral tablet taken daily, proved effective in resolving MASH without aggravating fibrosis and enhancing liver fibrosis during Phase 3 clinical trials. Thus, this revolutionizes the treatment approach by giving a non-invasive option, eliminating the necessity for liver biopsies and significantly enhancing patient access and outcome for fatty liver disease management.
Which Companies Are Contributing Significantly To The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals
Access The Complete Report Here:
Which Region Holds The Greatest Opportunity For Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Expansion?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=20876&type=smp
Browse Through More Reports Similar to the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market 2025, By The Business Research Company
Metabolic Disorders Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Cardiometabolic Diseases Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report
Comprehensive Metabolic Panel Cmp Testing Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
